The present invention provides a data analytic scheme for screening biomarkers for differential diagnosis of the status of Parkinson's disease, Parkinson's disease with mild cognitive impairment, Parkinson's disease dementia, Alzheimer's disease, and/or multiple system atrophy, the methodology implementing the same and the results of the screening thereof. Biomedical Oriented Logistic Dantzig Selector (BOLD Selector) was developed to identify candidate microRNAs and extracellular vesicle proteins effective at discerning between any two of the above mentioned disease categories from profiling results. The prediction models are finalized by establishing logistic regression formula for each pair of patient group differentiation.

The present invention relates to Abhydrolase containing domain 5 (ABHDS) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHDS for the identification of novel compounds which are useful for the treatment of heart failure.

The present invention is directed towards methods for treating non-alcoholic fatty liver disease (NAFLD) in a patient and determining prognosis of NAFLD in a patient.

Described herein are methods of cancer diagnosis through monitoring the presence and activity of the KANSL1 gene, and particularly the effects of KANSL1 overexpression on specific histone acetylation. Cancer treatment with histone acetyltransferase inhibitors and deacetylase agents is also described.

The present invention relates to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHD5 for the identification of novel compounds which are useful for the treatment of heart failure.

A mutant Bacillus subtilis, which does not express a functional KASIIIA and/or KASIIIB, and method of making; a mutant Rhodospirillum rubrum, which does not express a functional PhaC1, PhaC2, and/or PhaC3, and method of making; method of characterizing substrate specificity of KASIII; method of making mutant KASIII with altered substrate specificity and/or altered level of activity and nucleic acid, vector, host cell/organism, and mutant KASIII; an in vitro, high-throughput spectrophotometric method of assaying KASIII activity; and materials and methods for using KASIII for production of bi-functional fatty acids and the materials so produced.

Embodiments of the present disclosure provide a method for treating cellular inflammation induced by AFB1, comprising administering to a patient an agent that increases a content or an expression level of miR-9, wherein the agent that increases the content or the expression level of miR-9 is miR-9 mimics or an expression vector containing miR-9, a nucleotide sequence of the miR-9 mimics is shown in SEQ ID No. 5 and a SEQ ID No. 6, and a nucleotide sequence of the miR-9 is shown in SEQ ID No. 5. The present disclosure increases the content or the expression level of miR-9 to antagonize an upstream signaling, block an occurrence of inflammatory response, and inhibit a pro-inflammatory effect of AFB1 on glomerular podocyte.

Disclosed is a new method for improving the quality of platelets. It is disclosed for the first time that the molecular of carnitine palmitoyl transferase II (CPT2) of the platelet mitochondrial inner membrane is critical to the survival, preparation and storage of platelets, the reduction of CPT2 protein expression and/or activity seriously affects the quality of platelets, and the normal or high expression of the protein improves the quality of platelets. By means of directly and indirectly influencing or modifying CPT2 protein, the effect of CPT2 on platelets is verified at multiple angles, and a pathway and endogenous or exogenous molecules having a key effect of maintaining activity of platelets are disclosed. Therefore, the CPT2 itself or an up-regulator thereof can be used for maintaining the activity of platelets, and maintaining or improving the storage quality of platelets, and can also be used for screening substances capable of maintaining the activity of platelets or improving the storage quality thereof on the basis of the CPT2 or the signal pathway involving same and using same as a target.

The present invention provides a system and methods for detecting long-range cis-regulatory element (CRE) activities in a nucleic acid molecule obtained from a cell sample, the system comprising: one or more components for measuring multi-omics from a single nucleic acid molecule obtained from the cell sample, wherein the multi-omics measurements comprise one or more of: three-dimensional chromosomal conformation, CpG methylation, GpC accessibility, single nucleotide polymorphisms (SNPs); or one or more combinations thereof, and one or more components for measuring a transcriptome of the cell sample; wherein the system is capable of profiling a plurality of long-range CREs within the nucleic acid molecule obtained from the cell sample.

Elevated levels of spermidine/spermine N.sup.1-acetyltransferase (SSAT) gene expression expression were observed in breast, prostate and lung cancer cell lines. Elevated levels of SSAT gene expression were verified in tissues from patients with breast, prostate and lung cancer. Elevated SSAT gene expression is elevated in different human cancers and elevated SSAT gene expression may accordingly serve as a companion diagnostic biomarker for detection and monitoring of cancer progression.